Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 19, 2010
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2010, as well as guidance for...
-
Oct 13, 2010Major advance in guidewire technology for challenging peripheral interventions
Boston Scientific Corporation (NYSE: BSX) today announced the global launch of its Journey™ Guidewire, an innovative 0.014" guidewire designed for use in...
-
Oct 7, 2010
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30,...
-
Sep 28, 2010MADIT II eight-year outcomes analysis shows that one life is saved for every eight patients who receive an ICD
Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of an analysis of long-term data from the MADIT II clinical trial in the...
-
Sep 25, 2010
Boston Scientific Corporation (NYSE: BSX) today announced three-year follow-up data from the HORIZONS-AMI trial. The trial, sponsored by the...
-
Sep 22, 2010Company presents one-year clinical data at TCT on its platinum chromium paclitaxel-eluting coronary stent from PERSEUS trial
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing...
-
Sep 22, 2010Results of TAXUS ATLAS clinical program presented at TCT
Boston Scientific Corporation (NYSE: BSX) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global,...
-
Sep 21, 2010Nine-month results from PLATINUM clinical program presented at TCT
Boston Scientific Corporation (NYSE: BSX) today announced data from its PLATINUM QCA study, which is designed to evaluate the Company's PROMUS Element™...
-
Sep 21, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that its PROMUS® Element™ Everolimus-Eluting Coronary Stent System has received CE...
-
Sep 20, 2010Asthmatx offers first FDA-approved non-drug procedure for the treatment of severe asthma
Boston Scientific Corporation (NYSE: BSX) today announced the signing of a definitive merger agreement, under which Boston...
-
Sep 16, 2010FDA approval is based on results from the Company's landmark MADIT-CRT trial
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for...
-
Sep 14, 2010Company to present clinical data on its platinum chromium PROMUS® Element™ and TAXUS® Element™ Coronary Stent Systems
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular Research...
-
Sep 2, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Conference on September 14th in New...
-
Aug 19, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that results from studies involving the Company's Women's Health products will be...
-
Aug 11, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that it has been notified by the U.S. Food and Drug Administration that all issues cited...
-
Aug 3, 2010EVOLVE trial to evaluate Company's fourth-generation SYNERGY™ drug-eluting coronary stent
Boston Scientific Corporation (NYSE: BSX) today announced the start of patient enrollment in the EVOLVE clinical trial, which is designed to assess...
-
Jul 29, 2010Company now offers pain specialists the most comprehensive portfolio of SCS percutaneous leads
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration approval of two spinal cord stimulation (SCS) leads for...
-
Jul 29, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the BMO Capital Markets Healthcare Conference on August 5th in New York....
-
Jul 26, 2010Company expands market-leading family of neurovascular stents
Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launches of the Neuroform EZ™ Stent System, its fourth-generation...
-
Jul 20, 2010
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the second quarter ended June 30, 2010, as well as guidance for net...
-
Jul 8, 2010
Boston Scientific Corporation (NYSE: BSX) today announced enrollment of the first patient in its MultiSENSE clinical trial. The trial is designed to...
-
Jul 7, 2010
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2010...
-
Jun 24, 2010Two new splitters allow multi-site placement of up to four spinal cord stimulation leads
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration approval and launch of two spinal cord stimulation...
-
Jun 23, 2010
Boston Scientific Corporation (NYSE: BSX) today announced the successful syndication of a new $1 billion, three-year term loan and a new $2...
-
Jun 21, 2010Longer balloons provide physicians more options for treating peripheral artery disease
Boston Scientific Corporation (NYSE: BSX) today announced that 22 new balloon sizes have been added to the PolarCath® Peripheral Dilatation...